Significant pain variability in persons with, or at high risk of, knee osteoarthritis: preliminary investigation based on secondary analysis of cohort data by Parry, E et al.
RESEARCH ARTICLE Open Access
Significant pain variability in persons with,
or at high risk of, knee osteoarthritis:
preliminary investigation based on
secondary analysis of cohort data
Emma Parry1* , Reuben Ogollah2 and George Peat3
Abstract
Background: While knee osteoarthritis (OA) is characterised as a slowly progressive disease, acute flares, episodes of
severe pain, and substantial fluctuations in pain intensity appear to be part of the natural history for some patients. We
sought to estimate what proportion of symptomatic community-dwelling adults might be affected, and to identify
patient and problem characteristics associated with higher risk of such variability in pain.
Methods: We analysed data collected at baseline, 18, 36, 54, and 72 month follow-up of a prospective cohort of
symptomatic adults aged over 50 years with current/recent knee pain. At each time point we estimated the proportion
of participants reporting 'significant pain variability' (defined as worst pain intensity in the past 6 months ≥5/10 and ≥2
points higher than average pain intensity during the same 6-month period). The associations between significant pain
variability and demographic, socioeconomic, lifestyle, clinical, radiographic, and healthcare utilisation factors measured
at baseline were estimated by adjusted odds ratios and 95% confidence intervals (aOR; 95%CI) from multivariable
discrete-time survival analysis.
Results: Seven hundred and nineteen participants were included in the final analysis. At each time point, 23–32% of
participants were classed as reporting significant pain variability. Associated factors included: younger age (aOR (per
year): 0.96; 95% CI 0.94, 0.97), higher BMI (per kg/m2:1.03; 1.01, 1.06), higher WOMAC Pain score (per unit: 1.06; 1.03, 1.
10), longer time since onset (e.g. 1–5 years vs < 1 year: 1.79; 1.16, 2.75) and morning stiffness (≤30 min vs none: 1.43; 1.
10, 1.85). The models accounting for multiple periods of significant symptom variability found similar associations.
Conclusions: Our findings are consistent with studies showing that, for some patients OA symptoms are significantly
variable over time. Future prospective studies on the nature and frequency of flare ups are needed to help determine
triggers and their underlying pathophysiology in order to suggest new avenues for effective episode management of
OA to complement long-term behaviour change.
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Background
Longitudinal studies of knee osteoarthritis (OA) with re-
peated measurements over 5-6 years have suggested that
symptoms typically follow relatively stable long-term tra-
jectories [1–5]. However, these can mask considerable
within-person variability [6–8]. Of particular interest are
acute flares and episodes of uncharacteristically severe
pain that have been suggested to occur in both the early
and advanced stages of OA and which are associated
with distress and loss of function, particularly when
unpredictable [9].
Flare design trials, in which usual medication is with-
drawn with the intention of inducing an acute increase in
pain within a specified time period are well established. For
example, a recent systematic review identified 33 definite or
possible flare design trials evaluating non-steroidal anti-
inflammatory drugs (NSAID) [10]. The ‘natural occurrence’
of such flares has received less attention although there is a
growing body of observational research on these phenom-
ena under a variety of labels (“flares”, “acute events”,
“episodes”, “exacerbations”). These include studies that have
attempted to define an osteoarthritis flare [11, 12], to
understand the role of inflammation in these acute events
[13, 14], to identify triggers [15] and to describe their
impact on productivity [16].
Despite this growing body of research there is an
outstanding gap of epidemiological evidence on how com-
mon these flare ups may be and the type of patients that
are experiencing them. The largest quantitative study by
Marty et al. [11] produced a scoring tool to determine those
experiencing potential knee OA flare ups but this has not
yet been widely adopted clinically or in research. Factors
that have been critically important in defining flare ups in
other diseases may be important in osteoarthritis. These in-
clude worsening of symptoms beyond normal day-to-day
variation requiring additional medication [17–19], that is
progressive [20] and is clinically significant [21]. Looking at
significant symptom variability in osteoarthritis is a starting
point.
The aim of our study was to generate a preliminary
initial estimate of the frequency of significant symptom
variability in a primary care population and assess if
there were any risk factors associated with them.
Methods
Design
This was a secondary analysis of prospective observa-
tional cohort data from a sample of community-dwelling
symptomatic adults – the Clinical Assessment Study of
the Knee (CAS(K)).
Study population
Participants were recruited from a two-stage cross-sectional
postal survey of all adults ages ≥50 years registered with
three general practices in North Staffordshire (irrespective
of actual consulting patterns). Respondents reporting pain
of any duration in or around the knee within the previous
12 months were invited to attend a research clinic at a local
National Health Service Hospital Trust. The study protocol
was approved by North Staffordshire Local Research Ethics
Committee (project number 1430) and details have been
published elsewhere [22, 23]. All participants provided writ-
ten informed consent to undergo clinical and radiographic
assessment. In addition, they were asked for consent to
medical record review to assist in excluding pre-existing
inflammatory disease. The inclusion criteria for the current
analysis were as follows: age ≥50 years, registered with one
of the participating general practices at the time of study,
responded to both postal questionnaires, consented to fur-
ther contact, and attended the research clinic. Participants
were excluded if they had incomplete baseline radiographs,
had not experienced knee pain within the six months prior
to clinic attendance, had a pre-existing diagnosis of inflam-
matory arthropathy in their medical records, or had had a
total knee replacement in their most affected knee. Partici-
pants who reported total knee replacement (TKR) after
baseline and up to 3 years were also excluded. Patients
reporting TKR after 3 years were censored at the 3 year
time point.
Baseline data collection
All data were planned and gathered prospectively. At
baseline, participants underwent a standardized clinical
interview and physical examination conducted by one of
six research therapists blinded to the findings from radiog-
raphy, postal questionnaires and medical records.
Participants filled in a brief self-complete questionnaire
about their knee symptoms on the day of their clinic
attendance.
Plain knee radiographs were obtained on the day of
clinic attendance. Three views were taken of each knee: a
weight-bearing semi-flexed posteroanterior (PA) view, ac-
cording to the protocol developed by Buckland-Wright et
al. [24], and lateral and skyline views, both in a supine
position with the knee flexed to 45°. The tibiofemoral joint
was assessed using the PA view and the posterior
compartment of the lateral view. The patellofemoral joint
was assessed using the skyline and lateral views.
Scoring of plain radiographs
A single reader (a consultant rheumatologist with exten-
sive training in assessing knee radiographs for knee OA),
blinded to all other information on participants, scored all
films. Films were scored for individual radiographic fea-
tures, including osteophytes, joint space width, sclerosis,
subluxation and chondrocalcinosis. PA and skyline views
were assigned a Kellgren and Lawrence (K&L) grade based
on these authors' original written descriptions [25]. The
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atlas developed by Burnett et al. [26] was used for the lat-
eral view.
For PA, K&L score, skyline K&L score and lateral osteo-
phytes, intra- and inter-reader reliability were assessed in a
subsample of 50 participants (100 knees) and found to be
very good (κ = 0.81–0.98 and 0.49–0.76, respectively) [27].
Follow-up data collection
Follow up surveys, which included 11-point numerical
rating scales (NRS) on current, average and worst knee
pain intensity over the past 6 months [28], were mailed
to Phase 2 participants at 18 months, 36 months,
54 months and 72 months.
Outcome measure
At baseline and at each follow-up point we classed partici-
pants as reporting ‘significant pain variability’ if their
recalled worst pain intensity in the past 6 months was ≥5
out of 10 and at least 2 points higher than recalled average
pain intensity in the same 6 month period. To be included
in the denominator, individuals had to be ‘at risk’ during
that interval (i.e. average pain intensity <9 out of 10).
This definition was chosen after referring to previous
studies of osteoarthritis flares which were described as
worsening usual pain [11, 13], within defined limits using
equivocal pain scales from flare design trials which set a
minimum threshold of 50 mm on a 100 mm visual
analogue scale (VAS) [29] and a pain increase of at least
20 mm on a 100 mm VAS or an increase of at least two
points on a 10 point scale, from baseline [30, 31]. Defini-
tions used in other musculoskeletal disorders such as
lower back pain [32] and non-musculoskeletal conditions
such as Chronic Obstructive Pulmonary Disease (COPD)
were used [33, 34] where worsening of symptoms is used
in addition to requiring different or extra medication. The
definitions are all reliant on change and difference in pain.
Putative predictors
Predictors available in the CAS(K) dataset were selected
for analysis on the basis of being shown in previous
studies to be associated with incidence and progression
of knee osteoarthritis [15, 35–39], pain outcomes [15] or
acute flare-ups [11] (Table 1).
Statistical analysis
The proportion of participants classed as experiencing sig-
nificant symptom variability was reported for each time
point. For each follow-up time point those experiencing
symptom variability at baseline were compared between
those followed up and not followed up to identify any
differences.
To estimate the association between the putative pre-
dictor variables and significant pain variability, we used
discrete-time survival analysis. For clinical history/
examination and radiographic severity predictors we
used information from only one knee per individual,
the “index knee”: the single painful knee in participants
with unilateral knee pain or the most painful knee in
Table 1 Summary of putative predictors and their source
Domain Indicator
Demographic Age; gender
Socioeconomic Employment Status(employed, other); Occupational classa (managerial and professional, intermediate, routine and
manual)
Attended further education; Married/cohabiting
Clinical history/Examination Time since onset of problem (<1 year, 1 to <5 years, 5 to <10 years, 10+ years); Problem started following injury;
Bilateral knee pain; Duration of morning stiffness; Knee given way during previous month; Visited a hospital
doctor about knee problem; Presence and severity of palpable knee effusion (none, mild, moderate/gross); Nodal
symptomatic hand OA
Radiographic Severity Overall severity of radiographic OA: index knee (none, mild, moderate/severe)b
Compartmental distribution of radiographic OA: index knee (none, isolated TFJ, isolated PFJ, combined PFJ-TFJ)
Lifestyle factors Body mass index (kg/m2); Current smoker (Yes/No); Physical activity levelc : sedentary (Yes/No); moderate (Yes/
No); high (Yes/No)
Mental Health HADS Anxiety and Depression subscale scores scale
Physical function SF-36 (PF-10 subscale)
Knee-specific pain and functional
limitation
WOMAC Pain and Function subscale scores
Hospital Anxiety and Depression scale [54]; OA Osteoarthritis; PF-10 Medical Outcomes Study SF-36 Physical Functioning subscale [55]; SD Standard deviation;
WOMAC Western Ontario & McMaster Universities Osteoarthritis Index [56]
a Derived from National Socio-economic Classification [57]
b Mild = KL2 (PA or skyline view) or grade 1 osteophytes (lateral view); Moderate/severe = KL ≥ 3 (PA or skyline view) or grade 3 osteophytes (lateral view) [58]
c Twenty-three physical activity items were originally included. Those that were difficult to quantify were excluded from this analysis for example; ‘go out for a
walk’ and ‘go out to work’. We chose 6 items which were then categorised into sedentary (‘spend most or all of day in bed or chair’), moderate (‘walks of a least a
quarter of a mile’ and ‘walks of two miles’) and vigorous physical activity (‘play a sport’, ‘heavy gardening’ and ‘heavy DIY work at home’). These measures were
included if it was reported that they were done on ‘all, most or some days’
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individuals with bilateral knee pain. Discrete-time hazard
survival models become models for dichotomous response
when the data have been expanded to person-period data
with one observation for each year the person is at risk.
For each follow-up time point, we constructed an indica-
tor variable on whether the patient had experienced
significant pain variability in the 6 month period or not
and estimated the hazard of significant pain variability
using logistic discrete-time hazards model. The outcome
was right censored at 72 months, which was the last
follow-up time. Individuals who were lost to follow-up or
withdrew from the study before the period of significant
symptom variability was recorded, were also censored. To
adjust for changes in proportion reporting significant pain
variability over time, we included dummy variables for each
follow-up time in all models. Two sets of analyses were
conducted. We first modelled the time to first period of
significant pain variability, ignoring additional subsequent
periods of significant pain variability reported by the partici-
pant. We then used multilevel discrete-time survival
(frailty) models to take into account recurrent periods of
significant pain variability within participants. In the frailty
model method, the association between periods of signifi-
cant pain variability is explicitly modelled as a random-
effect term. The frailty model was estimated using logistic
discrete-time hazards model with random effects.
The association between each predictor and outcome
was estimated and those with P-value <0.20 were selected
for inclusion in the multivariable models. Tests of multi-
collinearity were performed first by pairwise correlations
(one variable excluded if correlation coefficient >0.7) and
then by variance inflation factor (VIF >5 considered as
evidence of collinearity). We used a manual backward
elimination procedure to remove variables from the multi-
variable model until only factors with a P-value <0.05 were
retained in the final model. An a priori decision was made
to include age and gender in the final models. All analyses
were performed using Stata 13 [40].
Results
Eight hundred and nineteen people attended the re-
search clinic, of whom 719 participants were eligible for
inclusion for the baseline analysis (54% female; mean
age 67.3 (SD 8.5) years; mean BMI 29.3 (SD 5.0) kg/m2).
There was no strong evidence of selective loss to follow-
up related to presence of significant pain variability at
baseline (Additional file 1 Table S1).
Participants classed as having at least one period of
‘significant pain variability’
Between 23 and 32% of participants were estimated to
have experienced significant pain variability at each of the
five time points (Table 2). Across the entire cohort follow
up period 363 (47%) participants reported no periods, 202
(27%) reported one period, 90 (12%) reported two periods,
63 (8%) reported three periods, 30 (4%) reported four
periods and 13 (2%) reported five periods of significant
pain variability. Table 3 presents the descriptive statistics
for participants reporting at least one period of significant
pain variability.
Factors associated with time to first period of significant
pain variability
Based on the outcome of time to first period of signifi-
cant symptom variability, baseline measures associated
with a higher risk of symptom variability in the adjusted
analysis were: younger age (OR (per year): 0.96; 95% CI
0.94, 0.97), higher BMI (per kg/m2: 1.03; 1.01, 1.06),
higher WOMAC knee pain scores (per unit: 1.05; 1.03,
1.10), longer time since onset (e.g. 1–5 years vs < 1 year:
Table 2 Proportion of patients reporting significant pain variability at each time point
Measurement point
Baseline
(n = 761)
18 months
(n = 679)
36 months
(n = 610)
54 months
(n = 503)
72 months
(n = 410)
Eligible respondents reporting significant pain variabilitya: n (%) 227 (32) 163 (26) 126 (23) 129 (27) 114 (30)
Average pain intensity in past 6 months (0-10NRS) 4.7 (1.7) 4.6 (1.8) 4.5 (1.6) 4.4 (1.5) 4.9 (1.9)
Worst pain intensity in past 6 months (0-10NRS) 7.6 (1.6) 7.5 (1.5) 7.3 (1.5) 7.1 (1.5) 7.6 (1.6)
Eligible respondents reporting no significant pain variability: n (%) 493 (68) 462 (74) 433 (77) 336 (72) 260 (70)
Average pain intensity in past 6 months (0-10NRS) 3.9 (2.3) 3.5 (2.5) 3.9 (2.6) 3.5 (2.7) 3.8 (2.5)
Worst pain intensity in past 6 months (0-10NRS) 4.1 (2.3) 3.7 (2.4) 4.1 (2.6) 3.8 (2.7) 4.1 (2.5)
Ineligible respondentsb: n (%) 41 (5) 42 (6) 40 (7) 31 (6) 30 (7)
Missing: n (%) 0 (0) 12 (2) 11 (2) 10 (2) 6 (1)
Figures are mean (standard deviation) unless otherwise stated. NRS Numerical Rating Scale
aworst pain intensity in past 6 months ≥5 and ≥2 points higher than average pain intensity in past 6 months
baverage pain intensity in past 6 months ≥ 9/10
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Table 3 Comparison of patient baseline characteristics of participants reporting at least one period of significant pain variability
potential flare
Periods of significant pain variability
≥1 None
n = 398 n = 363
Female gender 53 56
Age (years): mean (SD) 63.6 (8.2) 67.4 (8.7)
Employed 27 17
Attended full time education
after school
17 13
Married/cohabiting 76 68
Current smoker 11 10
Body Mass Index (kg/m2): mean (SD) 30.0 (5.3) 28.7 (4.8)
Routine/manual occupational classa 48 56
PF-10 physical function subscale
(0–100): mean (SD)
56.1 (27.9) 58.7 (30.1)
WOMAC knee pain (0–20): mean (SD) 6.5 (4.2) 5.6 (4.3)
WOMAC knee function (0–68): mean (SD) 21.1 (14.3) 18.5 (14.7)
HADS Anxiety (0–21): mean (SD) 6.8 (4.1) 6.3 (4.0)
HADS Depression (0–21): mean (SD) 4.8 (3.4) 4.2 (3.1)
Compartmental distribution of radiographic OA – index knee
Normal 33 31
Isolated tibiofemoral 5 3
Isolated patellofemoral 23 25
Combined tibiofemoral and patellofemoral 40 41
Overall severity of radiographic OA - index knee
Normal 33 31
Mild 28 30
Moderate/severe 39 39
Severity of knee effusion – index knee
None 67 66
Mild 23 23
Moderate/gross 10 11
Nodal symptomatic hand OA 15 18
Previous knee injury
None 65 71
Unilateral 26 23
Bilateral 9 5
Time since onset of knee problem
< 12 months 8 16
1 year to < 5 years 36 35
5 years to < 10 years 21 19
≥ 10 years 35 30
Duration of morning stiffness
None 35 46
≤30 min 60 50
>30 min 6 4
Parry et al. BMC Musculoskeletal Disorders  (2017) 18:80 Page 5 of 11
1.79; 1.16, 2.75) and morning stiffness (≤30 min vs none:
1.43; 1.10, 1.85) (Table 4).
Factors associated with recurrent periods of significant
pain variability
Based on the outcome of recurrent periods of significant
symptom variability, i.e. allowing for those experiencing
more than one episode, baseline measures associated with
a higher risk of potential symptom variability in the ad-
justed analysis were: younger age (0.94; 0.91, 0.98), higher
BMI (1.04; 1.00,1.08), higher WOMAC knee pain scores
(1.10; 1.03,1.17), longer time since onset (e.g. 1–5 years vs
< 1 year: (2.23; 1.11, 4.46) and morning stiffness (≤30 min
vs none: 1.67; 1.07, 2.61) (Table 5).
Discussion
From our study we estimate that between a quarter and a
third of adults aged over 50 years with knee pain report
significant symptom variability. Such variability was asso-
ciated with younger age, longer history of knee problem,
higher BMI and more severe knee symptoms. Variability
was also more common in people reporting previous bilat-
eral knee injury, greater functional limitation, frequent
sedentary behaviour and higher anxiety and depression
scores at baseline although these associations were not
statistically significant after adjusting for covariates.
In the context of previous studies it appears that signifi-
cant variability in pain affects a large minority of persons
with, or at risk, of knee OA but that estimates are sensitive
to the definition and period of time and frequency of meas-
urement. Of previous studies employing latent class growth
analysis or growth mixture modelling to cohort data with
repeated measures of pain only the study by Leffondre et al
[41] identified a group of patients characterised by pain
variability. Their group of patients with ‘highly unstable
WOMAC total scores, with abrupt changes or short-term
fluctuations’ accounted for 18% of the community-dwelling
sample of adults aged over 55 years with hip or knee pain.
The failure of other studies to extract such a ‘fluctuating
pain’ latent class using similar methodology [2–5], may well
reflect the long intervals between re-measurements (typic-
ally a year). In studies of low back pain, those with weekly
or fortnightly pain measurements classed twice as many
patients into a ‘fluctuating’ trajectory than studies using
monthly measurement [42]. It must also be stressed that
within trajectory groups that have an average ‘stable’ trajec-
tory, members of these groups can still experience signifi-
cant variability in their pain at an individual level. A further
source of comparison is Ricci et al.’s [16] estimate from
NHANES I data that 38% of US workers aged 40–65 years
with arthritis (predominantly hip or knee pain) report ‘pain
exacerbations’. Like our study, they adopted the same mag-
nitude of increase in pain intensity to define these events (2
or more points on 0-10NRS) although the Ricci study was
based on a 2-week recall period.
The extent to which our own, and any of these previous
studies, provides insights into the frequency of pain exacer-
bations or flares is limited by the data available. As noted
by Marty [11] and in consensus work for flare definition in
other rheumatic diseases [43, 44], flares are probably best
thought of as multidimensional constructs. With the data
available to us we could not verify the speed of onset, dur-
ation, or other features (e.g. swelling, limping) that may be
important in distinguishing acute flares from other forms
of variability within the natural history of osteoarthritis
pain. An important limitation of our study is the potential
misclassification bias as a result of recall error. We
hypothesise that patients with increased pain closer to the
measurement time points may have overestimated their
average and worst pain scores whereas those with fewer
pain fluctuations or no increase in pain close to the meas-
urement time points are likely to have underestimated their
pain scores over the previous 6 months. The overall impact
of this on our results is uncertain. In addition, the long
period of recall may be particularly prone to ‘forward tele-
scoping’ where an event is reported more recently than it
actually happened [45, 46]. In our analysis we have used the
‘average’ and ‘worst’ pain scores taken from the Von Korff
pain grade. These were chosen as they were similar but
unfortunately not comparable to outcomes used in flare
design trials. Flare-ups are identified in drug withdrawal
trials by comparing baseline pain scores to worst pain
scores. These limitations are only likely to be resolved by
prospective studies with frequent repeated measures over
clinically relevant time periods incorporating the concept of
pain variability
Table 3 Comparison of patient baseline characteristics of participants reporting at least one period of significant pain variability
potential flare (Continued)
Knee given way during past month 32 27
Seen hospital doctor about knee 27 20
Frequent sedentary activity 11 8
Frequent moderate activity 54 55
Frequent vigorous activity 28 28
Figures are column percentages unless otherwise stated. Hospital Anxiety and Depression scale [54]; OA Osteoarthritis; PF-10 Medical Outcomes Study SF-36
Physical Functioning subscale [55]; SD Standard deviation; WOMAC Western Ontario & McMaster Universities Osteoarthritis Index [56]
a Derived from National Socio-economic Classification [57]
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Table 4 Patient baseline characteristics associated with significant pain variability based on discrete-time logit model (first outcome)
Unadjusted Adjusteda
Reference OR (95% CI) aOR (95% CI)
Male gender Female 1.15 (0.92, 1.45) 1.22 (0.96, 1.55)
Age (years) per year 0.96 (0.95, 0.98) 0.96 (0.94, 0.97)
Body mass index (kg/m2) per kg/m2 1.05 (1.03, 1.08) 1.03 (1.01, 1.06)
Occupational class Managerial/professional
Intermediate 0.90 (0.56, 1.45)
Routine and manual 0.76 (0.51, 1.12)
PF-10 physical function (0–100) per unit 0.99 (0.99, 0.99) ns ns
WOMAC knee pain (0–20) per unit 1.08 (1.05, 1.11) 1.06 (1.03, 1.10)
WOMAC knee function (0–68) per unit 1.02 (1.01, 1.03) mc mc
Compartmental distribution of radiographic OAb Normal
Isolated tibiofemoral 1.03 (0.58, 1.81)
Isolated patellofemoral 0.94 (0.70, 1.28)
Combined tibiofemoral and patellofemoral 1.06 (0.81, 1.38)
Overall severity of radiographic OAb Normal
Mild 0.94 (0.70, 1.25)
Mod/severe 1.08 (0.82, 1.41)
HADS anxiety (0–21) per unit 1.04 (1.01, 1.07) mc mc
HADS depression (0–21) per unit 1.07 (1.03, 1.10) ns ns
Previous knee injury None ns ns
Unilateral 1.25 (0.95, 1.64)
Bilateral 1.82 (1.17, 2.85)
Time since onset of knee problemb <1 year
1 year to < 5 years 1.97 (1.29, 3.01) 1.79 (1.16, 2.75)
5 years to < 10 years 1.94 (1.23, 3.05) 1.82 (1.15, 2.89)
≥10 years 2.02 (1.32, 3.08) 1.82 (1.18, 2.82)
Duration of morning stiffnessb None
≤30 min 1.63 (1.28, 2.07) 1.43 (1.10, 1.85)
>30 min 2.26 (1.34, 3.81) 1.44 (0.83, 2.50)
Knee given way during past monthb No 1.38 (1.08, 1.77) ns ns
Seen hospital doctor about kneeb No 1.61 (1.23, 2.10) ns ns
Severity of effusionb None
Mild 0.99 (0.77, 1.30)
Moderate/gross 1.15 (0.79, 1.67)
Nodal symptomatic hand OA No 0.90 (0.66, 1.24)
Frequent sedentary activity No 1.59 (1.07, 2.35)
Frequent moderate activity No 0.85 (0.68, 1.07)
Frequent vigorous activity No 0.88 (0.68, 1.13)
a Adjusted for all other variables; - indicates variables entered but not retained in multivariable model
b For index (most problematic) knee
Hospital Anxiety and Depression scale [54]; OA Osteoarthritis; OR Odds ratio; PF-10 Medical Outcomes Study SF-36 Physical Functioning subscale [55]; WOMAC
Western Ontario & McMaster Universities Osteoarthritis Index [56]; 95%CI 95% confidence interval
ns Non-significant in multivariable model
mc Variables omitted in the multivariable model due to multi-collinearity
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Table 5 Patient baseline characteristics associated with significant pain variability based on discrete-time frailty model (recurrent
outcome)
Unadjusted Adjusteda
Reference OR (95% CI) aOR (95% CI)
Male gender Female 1.30 (0.86, 1.97) 1.40 (0.93, 2.09)
Age (years) per year 0.95 (0.92, 0.98) 0.94 (0.91, 0.98)
Body mass index (kg/m2) per kg/m2 1.07 (1.02, 1.12) 1.04 (1.00, 1.08)
Occupational class Managerial/professional
Intermediate 0.95 (0.53, 1.70)
Routine and manual 0.77 (0.49, 1.22)
PF-10 physical function (0–100) per unit 0.99 (0.99, 0.99) ns ns
WOMAC knee pain (0–20) per unit 1.12 (1.04, 1.21) 1.10 (1.03, 1.17)
WOMAC knee function (0–68) per unit 1.03 (1.01, 1.05) mc mc
Compartmental distribution of radiographic OAb Normal
Isolated tibiofemoral 1.05 (0.49, 2.24)
Isolated patellofemoral 0.93 (0.62, 1.40)
Combined tibiofemoral and patellofemoral 1.07 (0.75, 1.53)
Overall severity of radiographic OAb Normal
Mild 0.93 (0.63, 1.36)
Mod/severe 1.10 (0.77, 1.57)
HADS anxiety (0–21) per unit 1.05 (1.00, 1.10) mc mc
HADS depression (0–21) per unit 1.11 (1.02, 1.21) ns ns
Previous knee injury No ns ns
Unilateral 1.27 (0.92, 1.76)
Bilateral 1.96 (1.02, 3.79)
Time since onset of knee problemb <1 year
1 year to < 5 years 2.38 (1.14, 4.97) 2.23 (1.11, 4.46)
5 years to < 10 years 2.32 (1.10, 4.89) 2.20 (1.08, 4.48)
≥10 years 2.40 (1.18, 4.92) 2.11 (1.12, 4.05)
Duration of morning stiffnessb None
≤30 min 2.23 (1.17, 4.23) 1.67 (1.07, 2.61)
>30 min 3.75 (1.16, 12.16) 1.71 (0.73, 3.98)
Knee given way during past month No 1.42 (1.06, 1.90) ns ns
Seen hospital doctor about knee No 1.89 (1.41, 3.13) ns ns
Severity of effusion None
Mild 0.99 (0.69, 1.42)
Moderate/gross 1.18 (0.72, 1.92)
Nodal symptomatic hand OA No 0.80 (0.48, 1.35)
Frequent sedentary activity No 2.00 (0.96, 4.19)
Frequent moderate activity No 0.79 (0.56, 1.13)
Frequent vigorous activity No 0.79 (0.51, 1.23)
a Adjusted for all other variables; - indicates variables entered but not retained in multivariable model
brelates to index (most problematic) knee
Hospital Anxiety and Depression scale [54]; OA Osteoarthritis; OR Odds ratio; PF-10 Medical Outcomes Study SF-36 Physical Functioning subscale [55]; WOMAC
Western Ontario & McMaster Universities Osteoarthritis Index [56]; 95%CI 95% confidence interval
ns Non-significant in final model
mc Variables omitted in the multivariable model due to multi-collinearity
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The pattern of associations found in our study is con-
sistent with previous findings for some risk factors but
not others. Higher BMI, pain intensity, stiffness, and
functional limitation have been found to be associated
with flares in previous studies [11, 16]. By contrast, our
finding of an increased risk of potential flare with youn-
ger age was found by neither Marty nor Ricci which may
reflect the duration of data collection. Bouts of heavy
physical activity [47], buckling and knee injury [48] and
worsening mental health [37] have previously been
shown in case-crossover designs to be associated with
pain flares. The fact that our study found no association
between these factors measured at baseline and episodes
of worsened pain occurring months and years later may
simply affirm the need to regard these factors as time-
varying, proximal triggers. From influential qualitative
studies by Gooberman-Hill et al [49] and Hawker et al [9],
pain variability is thought to be a particular feature in the
early and the advanced stages of osteoarthritis. In our
study we found no strong relationship between significant
variability in pain and severity of radiographic knee OA
suggesting that this may happen across the spectrum of
the disease. As noted above, our data do not permit us to
explore further the quality or predictability of episodes of
severe pain: dimensions identified by patients as critical to
their ability to cope [12, 50]. If correct, our finding that
younger age, male gender, and BMI are associated with
higher risk of significant symptom variability, might imply
an important role for joint loading in provoking episodes
of severe pain and acute flares.
Conclusion
Up to a third of community-dwelling symptomatic adults
recall significant variability in knee pain that includes
periods of severe pain. Such variability occurs across the
spectrum of radiographic severity of knee osteoarthritis. A
larger body of work, as has been done for other diseases
such as COPD (Chronic Obstructive Pulmonary Disease),
is needed to reliably determine the characteristics of those
who experience significant symptom variability, including
acute flares [51], to assess burden [52], and to guide
prevention [53].
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